Business Context and Reporting Period
Company: Cardo Medical, Inc. (Note: Input metadata referenced "Biocardia," but the filing text identifies the registrant as Cardo Medical, Inc.)
Reporting Period: Quarterly period ended March 31, 2010.
Business Overview: An orthopedic medical device company specializing in reconstructive joint devices (knee, hip) and spinal surgical devices. The company operates two reportable segments: Reconstructive Division and Spine Division.
Stock Status: Quoted on the OTC Bulletin Board under symbol CDOM. As of May 10, 2010, 230,293,141 shares of common stock were outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Sales | $902 | $432 |
| Gross Profit | $730 | $350 |
| Gross Margin | 80.9% | 81.1% |
| Net Loss | $(1,455) | $(1,224) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.01) |
| Cash and Equivalents (End of Period) | $3,688 | $1,680 |
| Net Cash Used in Operating Activities | $(935) | $(983) |
| Net Cash Used in Investing Activities | $(350) | $(432) |
| Total Assets | $15,089 | $15,588 |
| Accumulated Deficit | $(12,620) | $(11,165) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by $470,000 (109%) to $902,000. This was driven primarily by a $404,000 increase in Spine Division sales due to the introduction of interbody spinal devices. Reconstructive Division sales increased slightly, though Knee sales saw a slight drop.
- Expense Increases:
- R&D Expenses: Increased by $240,000 to $286,000, attributed to direct labor allocations and custom instrument volume.
- SG&A Expenses: Increased by $370,000 to $1,906,000. Drivers included a $190,000 rise in sales commissions, $71,000 increase in depreciation/amortization, and $101,000 increase in professional fees.
- Working Capital: Accounts receivable increased by $371,000 and inventories increased by $414,000 to support anticipated sales growth. Accounts payable and accrued expenses increased by $938,000.
- Segment Performance: The Spine Division generated a net income of $335,000, while the Reconstructive Division generated $69,000. Corporate expenses resulted in a loss of $1,859,000.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states that the company's losses, negative cash flows, and accumulated deficit raise substantial doubt about its ability to continue as a going concern. While the company raised nearly $6 million in Q4 2009, current funds are not projected to meet working capital needs for the next twelve months.
- Liquidity Plan: The company anticipates sustaining losses through Q3 2010 and expects to require outside capital (debt or equity) to fund operations. There is no assurance that financing will be available on acceptable terms.
- Guidance: No specific numerical guidance was provided. Management expects profit margins to remain consistent with 2009 levels, subject to sales mix fluctuations.
- Key Risks:
- Dependence on third-party payors (Medicare/Medicaid) for reimbursement.
- Reliance on single-source manufacturers.
- Need for additional capital to fund R&D and operations.
- Regulatory risks regarding FDA approvals and quality system regulations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.7 million cash balance against the projected burn rate and the timeline for securing additional financing.
- Customer Concentration: Review the concentration risk where two customers accounted for 43.7% of accounts receivable and 43.1% of net sales in Q1 2010.
- Inventory Valuation: Assess the $3.67 million inventory balance, which increased significantly, to ensure it aligns with actual sales velocity and is not at risk of obsolescence.
- Financing Terms: Investigate the terms of the $6 million raised in late 2009 and the likelihood of securing further equity or debt without excessive dilution or restrictive covenants.
- Reimbursement Status: Confirm the current status of reimbursement codes for the new interbody spinal devices driving the recent revenue spike.